Prednisolone
 Prednisolone Ophthalmic Suspension

drug-information.ru

|Prednisolone Prednisolone Ophthalmic Suspension

Drugs search, click the first letter of a drug name:


| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | 1 | 2 | 3 | 4 | 5 | 6 | 8 | 9  Home

Prednisolone


Generic Name: Prednisolone sodium phosphate
Dosage Form: Oral solution

*DESCRIPTION:

Prednisolone Sodium Phosphate, USP, Oral Solution is a dye free, colorless to light straw colored, bubblegum flavored solution. Each 5 mL (teaspoonful) of Prednisolone Sodium Phosphate, USP, Oral Solution contains 6.7 mg Prednisolone sodium phosphate (5 mg Prednisolone base) in a palatable, aqueous vehicle.

Prednisolone Sodium Phosphate, USP, Oral Solution also contains dibasic sodium phosphate, edetate disodium, methylparaben, purified water, sodium biphosphate, sorbitol, and bubblegum flavor.

Prednisolone sodium phosphate occurs as white or slightly yellow, friable granules or powder. It is freely soluble in water; soluble in methanol; slightly soluble in alcohol and in chloroform; and very slightly soluble in acetone and in dioxane.The chemical name of Prednisolone sodium phosphate is pregna-1,4-diene-3,20-dione, 11,17-dihydroxy-21-(phosphonooxy)-, disodium salt, (11β)-.The empirical formula is C21H27Na2O8P; the molecular weight is 484.39. Its chemical structure is:

Pharmacological Category: Glucocorticoid

CLINICAL PHARMACOLOGY:

Naturally occurring glucocorticoids (hydrocortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states.Their synthetic analogs are primarily used for their potent anti-inflammatory effects in disorders of many organ systems.

Prednisolone is a synthetic adrenocortical steroid drug with predominantly glucocorticoid properties.Some of these properties reproduce the physiological actions of endogenous glucocorticosteroids, but others do not necessarily reflect any of the adrenal hormones"normal functions;they are seen only after administration of large therapeutic doses of the drug. The pharmacological effects of Prednisolone which are due to its glucocorticoid properties include: promotion of gluconeogenesis;increased deposition of glycogen in the liver; inhibition of the utilization of glucose; anti-insulin activity; increased catabolism of protein; increased lipolysis;stimulation of fat synthesis and storage;increased glomerular filtration rate and resulting increase in urinary excretion of urate (creatinine excretion remains unchanged); and increased calcium excretion.

Depressed production of eosinophils and lymphocytes occurs, but erythropoiesis and production of polymorphonuclear leukocytes are stimulated. Inflammatory processes (edema, fibrin deposition, capillary dilatation, migration of leukocytes and phagocytosis) and the later stages of wound healing (capillary proliferation, deposition of collagen, cicatrization) are inhibited.

Prednisolone can stimulate secretion of various components of gastric juice. Suppression of the production of corticotropin may lead to suppression of endogenous corticosteroids. Prednisolone has slight mineralocorticoid activity, whereby entry of sodium into cells and loss of intracellular potassium is stimulated.This is particularly evident in the kidney, where rapid ion exchange leads to sodium retention and hypertension.

Prednisolone is rapidly and well absorbed from the gastrointestinal tract following oral administration.Prednisolone Sodium Phosphate, USP, Oral Solution produces a 14% higher peak plasma level of Prednisolone which occurs 20% faster than that seen with tablets. Prednisolone is 70-90% protein-bound in the plasma and it is eliminated from the plasma with a half-life of 2 to 4 hours. It is metabolized mainly in the liver and excreted in the urine as sulfate and glucuronide conjugates.

The systemic availability, metabolism and elimination of Prednisolone after administration of single weight-based doses (0.8 mg/kg) of intravenous (IV) Prednisolone and oral prednisone were reported in a small study of 19 young (23 to 34 years) and 12 elderly (65 to 89 years) subjects. Results showed that the systemic availability of total and unbound prednisolone, as well as interconversion between Prednisolone and prednisone were independent of age. The mean unbound fraction of Prednisolone was higher, and the steady-state volume of distribution (Vss) of unbound Prednisolone was reduced in elderly patients. Plasma Prednisolone concentrations were higher in elderly subjects, and the higher AUCs of total and unbound Prednisolone were most likely reflective of an impaired metabolic clearance, evidenced by reduced fractional urinary clearance of 6β-hydroxyprednisolone. Despite these findings of higher total and unbound Prednisolone concentrations, elderly subjects had higher AUCs of cortisol, suggesting that the elderly population is less sensitive to suppression of endogenous cortisol or their capacity for hepatic inactivation of cortisol is diminished.

INDICATIONS AND USAGE:

Prednisolone Sodium Phosphate, USP, Oral Solution is indicated in the following conditions:

1. Allergic States

Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis, atopic dermatitis, serum sickness; drug hypersensitivity reactions.

2. Dermatologic Diseases

Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome);exfoliative erythroderma; mycosis fungoides.

3. Edematous States

To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia.

4. Endocrine Disorders

Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis.

5. Gastrointestinal Diseases

To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis.

6. Hematologic Disorders

Idiopathic thrombocytopenic purpura in adults;selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia.

7. Neoplastic Diseases

For the treatment of acute leukemia and aggressive lymphomas in adults and children.

8. Nervous System

Acute exacerbations of multiple sclerosis.

9. Ophthalmic Diseases

Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia.

10. Respiratory Diseases

Symptomatic sarcoidosis;idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under "Allergic States"), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics.Studies support the efficacy of systemic corticosteroids for the treatment of these conditions:allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia.

11. Rheumatic Disorders

As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis;acute gouty arthritis;epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren"s syndrome, relapsing polychondritis, and certain cases of vasculitis.

12. Miscellaneous

Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); Trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents).

CONTRAINDICATIONS:

Systemic fungal infections.

Hypersensitivity to the drug or any of its components.

WARNINGS:

General:

In patients on corticosteroid therapy subjected to unusual stress, increased dosage of rapidly acting corticosteroids before, during and after the stressful situation is indicated.

Cardio-renal:

Average and large doses of hydrocortisone or cortisone can cause elevation of blood pressure, salt and water retention, and increased excretion of potassium. These effects are less likely to occur with the synthetic derivatives except when used in large doses.Dietary salt restriction and potassium supplementation may be necessary.All corticosteroids increase calcium excretion.

Endocrine:

Corticosteroids can produce reversible hypothalamic-pituitary adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal of treatment.

Metabolic clearance of corticosteroids is decreased in hypothyroid patients and increased in hyperthyroid patients. Changes in thyroid status of the patient may necessitate adjustment in dosage.

Infections (General):

Persons who are on drugs which suppress the immune system are more susceptible to infections than healthy individuals.There may be decreased resistance and inability to localize infection when corticosteroids are used.Infection with any pathogen including viral, bacterial, fungal, protozoan or helminthic infection, in any location of the body, may be associated with the use of corticosteroids alone or in combination with other immunosuppressive agents that affect humoral or cellular immunity, or neutrophil function. These infections may be mild to severe, and, with increasing doses of corticosteroids, the rate of occurance of infectious complications increases. Corticosteroids may also mask some signs of infection after it has already started.

Infections (Viral):

Chicken pox and measles, for example, can have a more serious or even fatal course in non-immune children or adults on corticosteroids. In such children or adults who have not had these diseases, particular care should be taken to avoid exposure. How the dose, route and duration of corticosteroid administration affect the risk of developing a disseminated infection is not known. The contribution of the underlying disease and/or prior corticosteroid treatment to the risk is also not known.If exposed to chicken pox, prophylaxis with varicella zoster immune globulin (VZIG) may be indicated. If exposed to measles, prophylaxis with immunoglobulin (IG) may be indicated. (See the respective package inserts for complete VZIG and IG prescribing information). If chicken pox develops, treatment with antiviral agents should be considered.

Ophthalmic:

Use of corticosteroids may produce posterior subcapsular cataracts, glaucoma with possible damage to the optic nerves, and may enhance the establishment of secondary ocular infections due to bacteria, fungi or viruses.The use of oral corticosteroids is not recommended in the treatment of optic neuritis and may lead to an increase in the risk of new episodes. Corticosteroids should not be used in active ocular herpes simplex.

Special pathogens:

Latent disease may be activated or there may be an exacerbation of intercurrent infections due to pathogens, including those caused by Candida, Mycobacterium, Ameba, Toxoplasma, Pneumocystis, Cryptococus, Nocardia, etc.

Corticosteroids may activate latent amebiasis. Therefore, it is recommended that latent or active amebiasis be ruled out before initiating corticosteroid therapy in any patient who has spent time in the tropics or in any patient with unexplained diarrhea.

Similarly, corticosteroids should be used with great care in patients with known or suspected Strongyloides (threadworm) infestation.In such patients, corticosteroid-induced immunosuppression may lead to Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia.

Corticosteroids should not be used in cerebral malaria.

Tuberculosis:

The use of Prednisolone in active tuberculosis should be restricted to those cases of fulminating or disseminated tuberculosis in which the corticosteroid is used for the management of the disease in conjunction with an appropriate antituberculous regimen.

If corticosteroids are indicated in patients with latent tuberculosis or tuberculin reactivity, close observation is necessary as reactivation of the disease may occur. During prolonged corticosteroid therapy these patients should receive chemoprophylaxis.

Vaccination:

Administration of live or live, attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of corticosteroids. Killed or inactivated vaccines may be administered, however, the response to such vaccines can not be predicted. Immunization procedures may be undertaken in patients who are receiving corticosteroids as replacement therapy, e.g., for Addison"s disease.

PRECAUTIONS:

General:

The lowest possible dose of corticosteroid should be used to control the condition under treatment, and when reduction in dosage is possible, the reduction should be gradual.

Since complications of treatment with glucocorticoids are dependent on the size of the dose and the duration of treatment, a risk/benefit decision must be made in each individual case as to dose and duration of treatment and as to whether daily or intermittent therapy should be used.

There is an enhanced effect of corticosteroids in patients with hypothyroidism and in those with cirrhosis.

Kaposi"s sarcoma has been reported to occur in patients receiving corticosteroid therapy, most often for chronic conditions. Discontinuation of cortico-steroids may result in clinical improvement.

Cardio-renal:

As sodium retention with resultant edema and potassium loss may occur in patients receiving cortico-steroids, these agents should be used with caution in patients with hypertension, congestive heart failure, or renal insufficiency.

Endocrine:

Drug-induced secondary adrenocortical insufficiency may be minimized by gradual reduction of dosage. This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted. Since mineralocorticoid secretion may be impaired, salt and/or a mineralocorticoid should be administered concurrently.

Gastrointestinal:

Steroids should be used with caution in nonspecific ulcerative colitis, if there is a probability of impending perforation, abscess or other pyogenic infection;diverticulitis;fresh intestinal anastomoses; active or latent peptic ulcer.

Signs of peritoneal irritation following gastrointestinal perforation in patients receiving corticosteroids may be minimal or absent.

Musculoskeletal:

Corticosteroids decrease bone formation and increase bone resorption both through their effect on calcium regulation (i.e. decreasing absorption and increasing excretion) and inhibition of osteoblast function.This, together with a decrease in the protein matrix of the bone secondary to an increase in protein catabolism, and reduced sex hormone production, may lead to inhibition of bone growth in children and adolescents and the development of osteoporosis at any age. Special consideration should be given to patients at increased risk of osteoporosis (i.e., postmenopausal women) before initiating corticosteroid therapy.

Neuro-psychiatric:

Although controlled clinical trials have shown corticosteroids to be effective in speeding the resolution of acute exacerbations of multiple sclerosis, they do not show that they affect the ultimate outcome or natural history of the disease. The studies do show that relatively high doses of corticosteroids are necessary to demonstrate a significant effect. (See DOSAGE AND ADMINISTRATION)

An acute myopathy has been observed with the use of high doses of corticosteroids, most often occurring in patients with disorders of neuromuscular transmission (e.g., myasthenia gravis), or in patients receiving concomitant therapy with neuromuscular blocking drugs (e.g., pancuronium). This acute myopathy is generalized, may involve ocular and respiratory muscles, and may result in quadriparesis. Elevation of creatinine kinase may occur.Clinical improvement or recovery after stopping corticosteroids may require weeks to years.

Psychic derangements may appear when corticosteroids are used, ranging from euphoria, insomnia, mood swings, personality changes, and severe depression, to frank psychotic manifestations. Also, existing emotional instability or psychotic tendencies may be aggravated by corticosteroids.

Ophthalmic:

Intraocular pressure may become elevated in some individuals. If steroid therapy is continued for more than 6 weeks, intraocular pressure should be monitored.

Information for Patients:

Patients should be warned not to discontinue the use of Prednisolone Sodium Phosphate, USP, Oral Solution abruptly or without medical supervision, to advise any medical attendants that they are taking Prednisolone Sodium Phosphate, USP, Oral Solution and to seek medical advice at once should they develop fever or other signs of infection.

Persons who are on immunosuppressant doses of corticosteroids should be warned to avoid exposure to chicken pox or measles. Patients should also be advised that if they are exposed, medical advice should be sought without delay.

Drug Interactions:

Drugs such as barbiturates, phenytoin, ephedrine, and rifampin, which induce hepatic microsomal drug metabolizing enzyme activity may enhance metabolism of Prednisolone and require that the dosage of PrednisoloneSodium Phosphate, USP, Oral Solution be increased.

Increased activity of both cyclosporin and corticosteroids may occur when the two are used concurrently. Convulsions have been reported with this concurrent use.

Estrogens may decrease the hepatic metabolism of certain corticosteroids thereby increasing their effect.

Ketoconazole have been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects.

Coadministration of corticosteroids and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports. Therefore, coagulation indices should be monitored frequently to maintain the desired anticoagulant effect.

Concomitant use of aspirin (or other non-steroidal anti-inflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects. Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia. The clearance of salicylates may be increased with concurrent use of corticosteroids.

When corticosteroids are administered concomitantly with potassium-depleting agents (i.e., diuretics, amphotericin-B), patients should be observed closely for development of hypokalemia.Patients on digitalis glycosides may be at increased risk of arrhythmias due to hypokalemia.

Concomitant use of anticholinesterase agents and corticosteroids may produce severe weakness in patients with myasthenia gravis. If possible, anticholinesterase agents should be withdrawn at least 24 hours before initiating corticosteroid therapy.

Due to inhibition of antibody response, patients on prolonged corticosteroid therapy may exhibit a diminished response to toxoids and live or inactivated vaccines. Corticosteroids may also potentiate the replication of some organisms contained in live attenuated vaccines. If possible, routine administration of vaccines or toxoids should be deferred until corticosteroid therapy is discontinued.

Because corticosteroids may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required.

Corticosteroids may suppress reactions to skin tests.

Pregnancy:

Teratogenic effects:

Pregnancy Category C.

Prednisolone has been shown to be teratogenic in many species when given in doses equivalent to the human dose. Animal studies in which Prednisolone has been given to pregnant mice, rats, and rabbits have yielded an increased incidence of cleft palate in the offspring.There are no adequate and well-controlled studies in pregnant women.Prednisolone Sodium Phosphate, USP, Oral Solution should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Infants born to mothers who have received corticosteroids during pregnancy should be carefully observed for signs of hypoadrenalism.

Nursing Mothers:

Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. Caution should be exercised when Prednisolone Sodium Phosphate, USP, Oral Solution is administered to a nursing woman.

Pediatric Use:

The efficacy and safety of Prednisolone in the pediatric population are based on the well-established course of effect of corticosteroids which is similar in pediatric and adult populations. Published studies provide evidence of efficacy and safety in pediatric patients for the treatment of nephrotic syndrome (>2 years of age), and aggressive lymphomas and leukemias (>1 month of age). However, some of these conclusions and other indications for pediatric use of corticosteroids, e.g., severe asthma and wheezing, are based on adequate and well-controlled trials conducted in adults, on the premises that the course of the diseases and their pathophysiology are considered to be substantially similar in both populations.

The adverse effects of Prednisolone in pediatric patients are similar to those in adults (see ADVERSE REACTIONS). Like adults, pediatric patients should be carefully observed with frequent measurements of blood pressure, weight, height, intraocular pressure, and clinical evaluation for the presence of infection, psychosocial disturbances, thromboembolism, peptic ulcers, cataracts, and osteoporosis. Children who are treated with corticosteroids by any route, including systemically administered corticosteroids, may experience a decrease in their growth velocity. This negative impact of corticosteroids on growth has been observed at low systemic doses and in the absence of laboratory evidence of HPA axis suppression (i.e., cosyntropin stimulation and basal cortisol plasma levels). Growth velocity may therefore be a more sensitive indicator of systemic corticosteroid exposure in children than some commonly used tests of HPA axis function. The linear growth of children treated with corticosteroids by any route should be monitored, and the potential growth effects of prolonged treatment should be weighed against clinical benefits obtained and the availability of other treatment alternatives. In order to minimize the potential growth effects of corticosteroids, children should be titrated to the lowest effective dose.

Geriatric Use:

Clinical studies of Prednisolone Sodium Phosphate, USP, Oral Solution did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience with Prednisolone sodium phosphate has not identified differences in responses between the elderly and younger patients. However, the incidence of corticosteroid-induced side effects may be increased in geriatric patients and appear to be dose-related. Osteoporosis is the most frequently encountered complication, which occurs at a higher incidence rate in corticosteroid-treated geriatric patients as compared to younger populations and in age-matched controls. Loss of bone mineral density appear to be greatest early on in the course of treatment and may recover over time after steroid withdrawal or use of lower doses (i.e., <5mg/day).Prednisolone doses of 7.5 mg/day or higher have been associated with an increased relative risk of both vertebral and nonvertebral fractures, even in the presence of higher bone density compared to patients with involutional osteoporosis.

Routine screening of geriatric patients, including regular assessments of bone mineral density and institution of fracture prevention strategies, along with regular review of Prednisolone indication should be undertaken to minimize complications and keep the Prednisolone dose at the lowest acceptable level. Co-administration of bisphosphonates has been shown to retard the rate of bone loss in corticosteroid-treated males and postmenopausal females, and these agents are recommended in the prevention and treatment of corticosteroid-induced osteoporosis.

It has been reported that equivalent weight-based doses yield higher total and unbound Prednisolone plasma concentrations and reduced renal and non-renal clearance in elderly patients compared to younger populations. However, it is not clear whether dosing reductions would be necessary in elderly patients, since these pharmacokinetic alterations may be offset by age related differences in responsiveness of target organs and/or less pronounced suppression of adrenal release of cortisol. Dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function (see CLINICAL PHARMACOLOGY).

ADVERSE REACTIONS (listed alphabetically under each subsection):

Cardiovascular: Hypertrophic cardiomyopathy in premature infants.

Dermatologic: Facial erythema; increased sweating; impaired wound healing; may suppress reactions to skin tests;petechiae and ecchymoses;thin fragile skin;urticaria; edema.

Endocrine: Decreased carbohydrate tolerance; development of cushingoid state;hirsutism;increased requirements for insulin or oral hypoglycemic agents in diabetes; manifestations of latent diabetes mellitus; menstrual irregularities; secondary adrenocortical and pituitary unresponsiveness, particularly in times of stress, as in trauma, surgery or illness; suppression of growth in children.

Fluid and Electrolyte Disturbances: Congestive heart failure in susceptible patients; fluid retention; hypertension; hypokalemic alkalosis;potassium loss;sodium retention.

Gastrointestinal: Abdominal distention;elevation in serum liver enzyme levels (usually reversible upon discontinuation); pancreatitis; peptic ulcer with possible perforation and hemorrhage; ulcerative esophagitis.

Metabolic: Negative nitrogen balance due to protein catabolism.

Musculoskeletal: Aseptic necrosis of femoral and humeral heads; loss of muscle mass; muscle weakness; osteoporosis; pathologic fracture of long bones; steroid myopathy; tendon rupture; vertebral compression fractures.

Neurological: Convulsions;headache;increased intracranial pressure with papilledema (pseudotumor cerebri), usually following discontinuation of treatment; psychic disorders; vertigo.

Ophthalmic: Exophthalmos;glaucoma;increased intraocular pressure; posterior subcapsular cataracts.

Other: Increased appetite; malaise; nausea; weight gain.

OVERDOSAGE:

The effects of accidental ingestion of large quantities of Prednisolone over a very short period of time have not been reported, but prolonged use of the drug can produce mental symptoms, moon face, abnormal fat deposits, fluid retention, excessive appetite, weight gain, hypertrichosis, acne, striae, ecchymosis, increased sweating, pigmentation, dry scaly skin, thinning scalp hair, increased blood pressure, tachycardia, thrombophlebitis, decreased resistance to infection, negative nitrogen balance with delayed bone and wound healing, headache, weakness, menstrual disorders, accentuated menopausal symptoms, neuropathy, fractures, osteoporosis, peptic ulcer, decreased glucose tolerance, hypokalemia, and adrenal insufficiency. Hepatomegaly and abdominal distention have been observed in children.

Treatment of acute overdosage is by immediate gastric lavage or emesis followed by supportive and symptomatic therapy. For chronic overdosage in the face of severe disease requiring continuous steroid therapy the dosage of Prednisolone may be reduced only temporarily, or alternate day treatment may be introduced.

DOSAGE AND ADMINISTRATION:

The initial dosage of PrednisoloneSodiumPhosphate, USP, Oral Solution may vary from 5 mL to 60 mL (5 to 60 mg Prednisolone base) per day depending on the specific disease entity being treated. In situations of less severity, lower doses will generally suffice while in selected patients higher initial doses may be required. The initial dosage should be maintained or adjusted until a satisfactory response is noted. If after a reasonable period of time, there is a lack of satisfactory clinical response, PrednisoloneSodium Phosphate, USP, Oral Solution should be discontinued and the patient placed on other appropriate therapy. IT SHOULD BE EMPHASIZED THAT DOSAGE REQUIREMENTS ARE VARIABLE AND MUST BE INDIVIDUALIZED ON THE BASIS OF THE DISEASE UNDER TREATMENT AND THE RESPONSE OF THE PATIENT. After a favorable response is noted, the proper maintenance dosage should be determined by decreasing the initial drug dosage in small decrements at appropriate time intervals until the lowest dosage which will maintain an adequate clinical response is reached. It should be kept in mind that constant monitoring is needed in regard to drug dosage.Included in the situations which may make dosage adjustments necessary are changes in clinical status secondary to remissions or exacerbations in the disease process, the patient"s individual drug responsiveness, and the effect of patient exposure to stressful situations not directly related to the disease entity under treatment; in this latter situation it may be necessary to increase the dosage of Prednisolone SodiumPhosphate, USP, Oral Solution for a period of time consistent with the patient"s condition. If after long term therapy the drug is to be stopped, it is recommended that it be withdrawn gradually rather than abruptly.

In the treatment of acute exacerbations of multiple sclerosis, daily doses of 200 mg of Prednisolone for a week followed by 80 mg every other day or 4 to 8 mg dexamethasone every other day for one month have been shown to be effective.

In pediatric patients, the initial dose of Prednisolone Sodium Phosphate, USP, Oral Solution may vary depending on the specific disease entity being treated. The range of initial doses is 0.14 to 2 mg/kg/day in three or four divided doses (4 to 60 mg/m2bsa/day).

The standard regimen used to treat nephrotic syndrome in pediatric patients is 60 mg/m2/day given in three divided doses for 4 weeks, followed by 4 weeks of single dose alternate-day therapy at 40 mg/m2/day.

The National Heart, Lung, and Blood Institute (NHLBI) recommended dosing for systemic prednisone, Prednisolone or methylPrednisolone in children whose asthma is uncontrolled by inhaled corticosteroids and long-acting bronchodilators is 1-2 mg/kg/day in single or divided doses. It is further recommended that short course, or "burst" therapy, be continued until a child achieves a peak expiratory flow rate of 80% of his or her personal best or symptoms resolve. This usually requires 3 to 10 days of treatment, although it can take longer. There is no evidence that tapering the dose after improvement will prevent a relapse.

For the purpose of comparison, the following is the equivalent milligram dosage of the various glucocorticoids:

Cortisone, 25 Triamcinolone, 4
Hydrocortisone, 20 Paramethasone, 2
Prednisolone, 5 Betamethasone, 0.75
Prednisone, 5 Dexamethasone, 0.75
Methylprednisolone, 4

These dose relationships apply only to oral or intravenous administration of these compounds. When these substances or their derivatives are injected intramuscularly or into joint spaces, their relative properties may be greatly altered.

HOW SUPPLIED:

Prednisolone Sodium Phosphate, USP, Oral Solution is a colorless to light straw colored solution containing 6.7 mg Prednisolone sodium phosphate (5 mg Prednisolone base) per 5 mL (teaspoonful).

NDC 0574-0148-04     120 mL bottle

Store at 4°-25°C (39°-77°F). May be refrigerated. Keep tightly closed and out of the reach of children.

Paddock Laboratories, Inc.
Minneapolis, MN 55427

(03-05)


Prednisolone Sodium Phosphate (Prednisolone Sodium Phosphate)
PRODUCT INFO
Product Code 0574-0148 Dosage Form SOLUTION
Route Of Administration ORAL DEA Schedule
INGREDIENTS
Name (Active Moiety) Type Strength
Prednisolone sodium phosphate (prednisolone) Active 6.7 MILLIGRAM  In 5 MILLILITER
dibasic sodium phosphate Inactive  
edetate disodium Inactive  
methylparaben Inactive  
water Inactive  
sodium biphosphate Inactive  
sorbitol Inactive  
bubble gum flavor Inactive  
IMPRINT INFORMATION
Characteristic Appearance Characteristic Appearance
Color Score
Shape Symbol
Imprint Code Coating
Size
PACKAGING
# NDC Package Description Multilevel Packaging
1 0574-0148-04 120 MILLILITER In 1 BOTTLE None

Revised: 09/2006





Where can I get more information about Prednisolone Prednisolone Ophthalmic Suspension ? We recommend to use www.Drugs.com

Typical mistypes for Prednisolone Prednisolone Ophthalmic Suspension
orednisolone prednisolone ophthalmic suspension, lrednisolone prednisolone ophthalmic suspension, -rednisolone prednisolone ophthalmic suspension, 0rednisolone prednisolone ophthalmic suspension, peednisolone prednisolone ophthalmic suspension, pdednisolone prednisolone ophthalmic suspension, pfednisolone prednisolone ophthalmic suspension, ptednisolone prednisolone ophthalmic suspension, p5ednisolone prednisolone ophthalmic suspension, p4ednisolone prednisolone ophthalmic suspension, prwdnisolone prednisolone ophthalmic suspension, prsdnisolone prednisolone ophthalmic suspension, prddnisolone prednisolone ophthalmic suspension, prrdnisolone prednisolone ophthalmic suspension, pr4dnisolone prednisolone ophthalmic suspension, pr3dnisolone prednisolone ophthalmic suspension, presnisolone prednisolone ophthalmic suspension, prexnisolone prednisolone ophthalmic suspension, precnisolone prednisolone ophthalmic suspension, prefnisolone prednisolone ophthalmic suspension, prernisolone prednisolone ophthalmic suspension, preenisolone prednisolone ophthalmic suspension, predbisolone prednisolone ophthalmic suspension, predmisolone prednisolone ophthalmic suspension, predjisolone prednisolone ophthalmic suspension, predhisolone prednisolone ophthalmic suspension, prednusolone prednisolone ophthalmic suspension, prednjsolone prednisolone ophthalmic suspension, prednksolone prednisolone ophthalmic suspension, prednosolone prednisolone ophthalmic suspension, predn9solone prednisolone ophthalmic suspension, predn8solone prednisolone ophthalmic suspension, predniaolone prednisolone ophthalmic suspension, prednizolone prednisolone ophthalmic suspension, prednixolone prednisolone ophthalmic suspension, prednidolone prednisolone ophthalmic suspension, prednieolone prednisolone ophthalmic suspension, predniwolone prednisolone ophthalmic suspension, prednisilone prednisolone ophthalmic suspension, prednisklone prednisolone ophthalmic suspension, prednisllone prednisolone ophthalmic suspension, prednisplone prednisolone ophthalmic suspension, prednis0lone prednisolone ophthalmic suspension, prednis9lone prednisolone ophthalmic suspension, prednisokone prednisolone ophthalmic suspension, prednisopone prednisolone ophthalmic suspension, prednisooone prednisolone ophthalmic suspension, prednisoline prednisolone ophthalmic suspension, prednisolkne prednisolone ophthalmic suspension, prednisollne prednisolone ophthalmic suspension, prednisolpne prednisolone ophthalmic suspension, prednisol0ne prednisolone ophthalmic suspension, prednisol9ne prednisolone ophthalmic suspension, prednisolobe prednisolone ophthalmic suspension, prednisolome prednisolone ophthalmic suspension, prednisoloje prednisolone ophthalmic suspension, prednisolohe prednisolone ophthalmic suspension, prednisolonw prednisolone ophthalmic suspension, prednisolons prednisolone ophthalmic suspension, prednisolond prednisolone ophthalmic suspension, prednisolonr prednisolone ophthalmic suspension, prednisolon4 prednisolone ophthalmic suspension, prednisolon3 prednisolone ophthalmic suspension, prednisolone orednisolone ophthalmic suspension, prednisolone lrednisolone ophthalmic suspension, prednisolone -rednisolone ophthalmic suspension, prednisolone 0rednisolone ophthalmic suspension, prednisolone peednisolone ophthalmic suspension, prednisolone pdednisolone ophthalmic suspension, prednisolone pfednisolone ophthalmic suspension, prednisolone ptednisolone ophthalmic suspension, prednisolone p5ednisolone ophthalmic suspension, prednisolone p4ednisolone ophthalmic suspension, prednisolone prwdnisolone ophthalmic suspension, prednisolone prsdnisolone ophthalmic suspension, prednisolone prddnisolone ophthalmic suspension, prednisolone prrdnisolone ophthalmic suspension, prednisolone pr4dnisolone ophthalmic suspension, prednisolone pr3dnisolone ophthalmic suspension, prednisolone presnisolone ophthalmic suspension, prednisolone prexnisolone ophthalmic suspension, prednisolone precnisolone ophthalmic suspension, prednisolone prefnisolone ophthalmic suspension, prednisolone prernisolone ophthalmic suspension, prednisolone preenisolone ophthalmic suspension, prednisolone predbisolone ophthalmic suspension, prednisolone predmisolone ophthalmic suspension, prednisolone predjisolone ophthalmic suspension, prednisolone predhisolone ophthalmic suspension, prednisolone prednusolone ophthalmic suspension, prednisolone prednjsolone ophthalmic suspension, prednisolone prednksolone ophthalmic suspension, prednisolone prednosolone ophthalmic suspension, prednisolone predn9solone ophthalmic suspension, prednisolone predn8solone ophthalmic suspension, prednisolone predniaolone ophthalmic suspension, prednisolone prednizolone ophthalmic suspension, prednisolone prednixolone ophthalmic suspension, prednisolone prednidolone ophthalmic suspension, prednisolone prednieolone ophthalmic suspension, prednisolone predniwolone ophthalmic suspension, prednisolone prednisilone ophthalmic suspension, prednisolone prednisklone ophthalmic suspension, prednisolone prednisllone ophthalmic suspension, prednisolone prednisplone ophthalmic suspension, prednisolone prednis0lone ophthalmic suspension, prednisolone prednis9lone ophthalmic suspension, prednisolone prednisokone ophthalmic suspension, prednisolone prednisopone ophthalmic suspension, prednisolone prednisooone ophthalmic suspension, prednisolone prednisoline ophthalmic suspension, prednisolone prednisolkne ophthalmic suspension, prednisolone prednisollne ophthalmic suspension, prednisolone prednisolpne ophthalmic suspension, prednisolone prednisol0ne ophthalmic suspension, prednisolone prednisol9ne ophthalmic suspension, prednisolone prednisolobe ophthalmic suspension, prednisolone prednisolome ophthalmic suspension, prednisolone prednisoloje ophthalmic suspension, prednisolone prednisolohe ophthalmic suspension, prednisolone prednisolonw ophthalmic suspension, prednisolone prednisolons ophthalmic suspension, prednisolone prednisolond ophthalmic suspension, prednisolone prednisolonr ophthalmic suspension, prednisolone prednisolon4 ophthalmic suspension, prednisolone prednisolon3 ophthalmic suspension, prednisolone prednisolone iphthalmic suspension, prednisolone prednisolone kphthalmic suspension, prednisolone prednisolone lphthalmic suspension, prednisolone prednisolone pphthalmic suspension, prednisolone prednisolone 0phthalmic suspension, prednisolone prednisolone 9phthalmic suspension, prednisolone prednisolone oohthalmic suspension, prednisolone prednisolone olhthalmic suspension, prednisolone prednisolone o-hthalmic suspension, prednisolone prednisolone o0hthalmic suspension, prednisolone prednisolone opgthalmic suspension, prednisolone prednisolone opbthalmic suspension, prednisolone prednisolone opnthalmic suspension, prednisolone prednisolone opjthalmic suspension, prednisolone prednisolone oputhalmic suspension, prednisolone prednisolone opythalmic suspension, prednisolone prednisolone ophrhalmic suspension, prednisolone prednisolone ophfhalmic suspension, prednisolone prednisolone ophghalmic suspension, prednisolone prednisolone ophyhalmic suspension, prednisolone prednisolone oph6halmic suspension, prednisolone prednisolone oph5halmic suspension, prednisolone prednisolone ophtgalmic suspension, prednisolone prednisolone ophtbalmic suspension, prednisolone prednisolone ophtnalmic suspension, prednisolone prednisolone ophtjalmic suspension, prednisolone prednisolone ophtualmic suspension, prednisolone prednisolone ophtyalmic suspension, prednisolone prednisolone ophthzlmic suspension, prednisolone prednisolone ophthslmic suspension, prednisolone prednisolone ophthwlmic suspension, prednisolone prednisolone ophthqlmic suspension, prednisolone prednisolone ophthakmic suspension, prednisolone prednisolone ophthapmic suspension, prednisolone prednisolone ophthaomic suspension, prednisolone prednisolone ophthalnic suspension, prednisolone prednisolone ophthalkic suspension, prednisolone prednisolone ophthaljic suspension, prednisolone prednisolone ophthalmuc suspension, prednisolone prednisolone ophthalmjc suspension, prednisolone prednisolone ophthalmkc suspension, prednisolone prednisolone ophthalmoc suspension, prednisolone prednisolone ophthalm9c suspension, prednisolone prednisolone ophthalm8c suspension, prednisolone prednisolone ophthalmix suspension, prednisolone prednisolone ophthalmiv suspension, prednisolone prednisolone ophthalmif suspension, prednisolone prednisolone ophthalmid suspension, prednisolone prednisolone ophthalmic auspension, prednisolone prednisolone ophthalmic zuspension, prednisolone prednisolone ophthalmic xuspension, prednisolone prednisolone ophthalmic duspension, prednisolone prednisolone ophthalmic euspension, prednisolone prednisolone ophthalmic wuspension, prednisolone prednisolone ophthalmic syspension, prednisolone prednisolone ophthalmic shspension, prednisolone prednisolone ophthalmic sjspension, prednisolone prednisolone ophthalmic sispension, prednisolone prednisolone ophthalmic s8spension, prednisolone prednisolone ophthalmic s7spension, prednisolone prednisolone ophthalmic suapension, prednisolone prednisolone ophthalmic suzpension, prednisolone prednisolone ophthalmic suxpension, prednisolone prednisolone ophthalmic sudpension, prednisolone prednisolone ophthalmic suepension, prednisolone prednisolone ophthalmic suwpension, prednisolone prednisolone ophthalmic susoension, prednisolone prednisolone ophthalmic suslension, prednisolone prednisolone ophthalmic sus-ension, prednisolone prednisolone ophthalmic sus0ension, prednisolone prednisolone ophthalmic suspwnsion, prednisolone prednisolone ophthalmic suspsnsion, prednisolone prednisolone ophthalmic suspdnsion, prednisolone prednisolone ophthalmic susprnsion, prednisolone prednisolone ophthalmic susp4nsion, prednisolone prednisolone ophthalmic susp3nsion, prednisolone prednisolone ophthalmic suspebsion, prednisolone prednisolone ophthalmic suspemsion, prednisolone prednisolone ophthalmic suspejsion, prednisolone prednisolone ophthalmic suspehsion, prednisolone prednisolone ophthalmic suspenaion, prednisolone prednisolone ophthalmic suspenzion, prednisolone prednisolone ophthalmic suspenxion, prednisolone prednisolone ophthalmic suspendion, prednisolone prednisolone ophthalmic suspeneion, prednisolone prednisolone ophthalmic suspenwion, prednisolone prednisolone ophthalmic suspensuon, prednisolone prednisolone ophthalmic suspensjon, prednisolone prednisolone ophthalmic suspenskon, prednisolone prednisolone ophthalmic suspensoon, prednisolone prednisolone ophthalmic suspens9on, prednisolone prednisolone ophthalmic suspens8on, prednisolone prednisolone ophthalmic suspensiin, prednisolone prednisolone ophthalmic suspensikn, prednisolone prednisolone ophthalmic suspensiln, prednisolone prednisolone ophthalmic suspensipn, prednisolone prednisolone ophthalmic suspensi0n, prednisolone prednisolone ophthalmic suspensi9n, prednisolone prednisolone ophthalmic suspensiob, prednisolone prednisolone ophthalmic suspensiom, prednisolone prednisolone ophthalmic suspensioj, prednisolone prednisolone ophthalmic suspensioh, rednisolone prednisolone ophthalmic suspension, pednisolone prednisolone ophthalmic suspension, prdnisolone prednisolone ophthalmic suspension, prenisolone prednisolone ophthalmic suspension, predisolone prednisolone ophthalmic suspension, prednsolone prednisolone ophthalmic suspension, predniolone prednisolone ophthalmic suspension, prednislone prednisolone ophthalmic suspension, prednisoone prednisolone ophthalmic suspension, prednisolne prednisolone ophthalmic suspension, prednisoloe prednisolone ophthalmic suspension, prednisolon prednisolone ophthalmic suspension, prednisolone prednisolone ophthalmic suspension, prednisolone prednisolone ophthalmic suspension, prednisolone rednisolone ophthalmic suspension, prednisolone pednisolone ophthalmic suspension, prednisolone prdnisolone ophthalmic suspension, prednisolone prenisolone ophthalmic suspension, prednisolone predisolone ophthalmic suspension, prednisolone prednsolone ophthalmic suspension, prednisolone predniolone ophthalmic suspension, prednisolone prednislone ophthalmic suspension, prednisolone prednisoone ophthalmic suspension, prednisolone prednisolne ophthalmic suspension, prednisolone prednisoloe ophthalmic suspension, prednisolone prednisolon ophthalmic suspension, prednisolone prednisoloneophthalmic suspension, prednisolone prednisolone phthalmic suspension, prednisolone prednisolone ohthalmic suspension, prednisolone prednisolone opthalmic suspension, prednisolone prednisolone ophhalmic suspension, prednisolone prednisolone ophtalmic suspension, prednisolone prednisolone ophthlmic suspension, prednisolone prednisolone ophthamic suspension, prednisolone prednisolone ophthalic suspension, prednisolone prednisolone ophthalmc suspension, prednisolone prednisolone ophthalmi suspension, prednisolone prednisolone ophthalmicsuspension, prednisolone prednisolone ophthalmic uspension, prednisolone prednisolone ophthalmic sspension, prednisolone prednisolone ophthalmic supension, prednisolone prednisolone ophthalmic susension, prednisolone prednisolone ophthalmic suspnsion, prednisolone prednisolone ophthalmic suspesion, prednisolone prednisolone ophthalmic suspenion, prednisolone prednisolone ophthalmic suspenson, prednisolone prednisolone ophthalmic suspensin, prednisolone prednisolone ophthalmic suspensio, rpednisolone prednisolone ophthalmic suspension, perdnisolone prednisolone ophthalmic suspension, prdenisolone prednisolone ophthalmic suspension, prendisolone prednisolone ophthalmic suspension, predinsolone prednisolone ophthalmic suspension, prednsiolone prednisolone ophthalmic suspension, prednioslone prednisolone ophthalmic suspension, prednisloone prednisolone ophthalmic suspension, prednisoolne prednisolone ophthalmic suspension, prednisolnoe prednisolone ophthalmic suspension, prednisoloen prednisolone ophthalmic suspension, prednisolon e prednisolone ophthalmic suspension, prednisolone prednisolone ophthalmic suspension, prednisolone p rednisolone ophthalmic suspension, prednisolone rpednisolone ophthalmic suspension, prednisolone perdnisolone ophthalmic suspension, prednisolone prdenisolone ophthalmic suspension, prednisolone prendisolone ophthalmic suspension, prednisolone predinsolone ophthalmic suspension, prednisolone prednsiolone ophthalmic suspension, prednisolone prednioslone ophthalmic suspension, prednisolone prednisloone ophthalmic suspension, prednisolone prednisoolne ophthalmic suspension, prednisolone prednisolnoe ophthalmic suspension, prednisolone prednisoloen ophthalmic suspension, prednisolone prednisolon eophthalmic suspension, prednisolone prednisoloneo phthalmic suspension, prednisolone prednisolone pohthalmic suspension, prednisolone prednisolone ohpthalmic suspension, prednisolone prednisolone opthhalmic suspension, prednisolone prednisolone ophhtalmic suspension, prednisolone prednisolone ophtahlmic suspension, prednisolone prednisolone ophthlamic suspension, prednisolone prednisolone ophthamlic suspension, prednisolone prednisolone ophthalimc suspension, prednisolone prednisolone ophthalmci suspension, prednisolone prednisolone ophthalmi csuspension, prednisolone prednisolone ophthalmics uspension, prednisolone prednisolone ophthalmic usspension, prednisolone prednisolone ophthalmic ssupension, prednisolone prednisolone ophthalmic supsension, prednisolone prednisolone ophthalmic susepnsion, prednisolone prednisolone ophthalmic suspnesion, prednisolone prednisolone ophthalmic suspesnion, prednisolone prednisolone ophthalmic suspenison, prednisolone prednisolone ophthalmic suspensoin, prednisolone prednisolone ophthalmic suspensino, pprednisolone prednisolone ophthalmic suspension, prrednisolone prednisolone ophthalmic suspension, preednisolone prednisolone ophthalmic suspension, preddnisolone prednisolone ophthalmic suspension, prednnisolone prednisolone ophthalmic suspension, predniisolone prednisolone ophthalmic suspension, prednissolone prednisolone ophthalmic suspension, prednisoolone prednisolone ophthalmic suspension, prednisollone prednisolone ophthalmic suspension, prednisoloone prednisolone ophthalmic suspension, prednisolonne prednisolone ophthalmic suspension, prednisolonee prednisolone ophthalmic suspension, prednisolone prednisolone ophthalmic suspension, prednisolone prednisolone ophthalmic suspension, prednisolone pprednisolone ophthalmic suspension, prednisolone prrednisolone ophthalmic suspension, prednisolone preednisolone ophthalmic suspension, prednisolone preddnisolone ophthalmic suspension, prednisolone prednnisolone ophthalmic suspension, prednisolone predniisolone ophthalmic suspension, prednisolone prednissolone ophthalmic suspension, prednisolone prednisoolone ophthalmic suspension, prednisolone prednisollone ophthalmic suspension, prednisolone prednisoloone ophthalmic suspension, prednisolone prednisolonne ophthalmic suspension, prednisolone prednisolonee ophthalmic suspension, prednisolone prednisolone ophthalmic suspension, prednisolone prednisolone oophthalmic suspension, prednisolone prednisolone opphthalmic suspension, prednisolone prednisolone ophhthalmic suspension, prednisolone prednisolone ophtthalmic suspension, prednisolone prednisolone ophthhalmic suspension, prednisolone prednisolone ophthaalmic suspension, prednisolone prednisolone ophthallmic suspension, prednisolone prednisolone ophthalmmic suspension, prednisolone prednisolone ophthalmiic suspension, prednisolone prednisolone ophthalmicc suspension, prednisolone prednisolone ophthalmic suspension, prednisolone prednisolone ophthalmic ssuspension, prednisolone prednisolone ophthalmic suuspension, prednisolone prednisolone ophthalmic susspension, prednisolone prednisolone ophthalmic susppension, prednisolone prednisolone ophthalmic suspeension, prednisolone prednisolone ophthalmic suspennsion, prednisolone prednisolone ophthalmic suspenssion, prednisolone prednisolone ophthalmic suspensiion, prednisolone prednisolone ophthalmic suspensioon, prednisolone prednisolone ophthalmic suspensionn, etc.



© Copyright by drug-information.ru 2001-2019. All rights reserved